Monitor for initiation of the Phase 2b trial in Q1 2027 and any subsequent data readouts. No near-term catalyst from this manufacturing milestone alone.
Price Chart
Executive Summary
Phio Pharmaceuticals announced the successful completion of its first commercial-scale cGMP batch of PH-762 drug substance, a key operational milestone supporting supply chain readiness for the planned Phase 2b clinical trial initiation in Q1 2027. The filing is a routine operational update with no financial data, and the forward-looking statements about future trials do not constitute a material directional event.
Key Facts
- First commercial-scale cGMP batch of PH-762 drug substance completed and released
- Batch manufactured per cGMP regulations, ICH Q7 guidelines, with Certificate of Analysis and Certificate of Compliance
- Validated drug substance to proceed to drug product completion for planned Phase 2b clinical study
- Phase 2b trial expected to be initiated in Q1 2027
- Process started approximately 16 months ago per CEO statement
Financial Impact
No financial figures disclosed in the filing
Risk Factors
- Phase 2b trial initiation may be delayed beyond Q1 2027
- Clinical-stage biotech with no approved products; reliance on future financing
- Forward-looking statements about commercialization are aspirational and subject to regulatory approval
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-032505 |
| Exhibit: ex_1023938.htm | 0001437749-26-032505 |
| Document: 0001437749-26-032505-index-headers.html | 0001437749-26-032505 |
| Document: 0001437749-26-032505-index.html | 0001437749-26-032505 |
| Document: 0001437749-26-032505.txt | 0001437749-26-032505 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | 8-K | $0.9345 | awaiting T+20 | awaiting T+20 | $0.8910 (−4.65%) |
Sep 14, 2026 6w ago | 8-K | $1.03 $0.9220 | ▼ −10.49% | ▼ −12.75% | $0.8910 (−13.50%) |
Aug 14, 2026 10w ago | DEFA14A | $1.06 $1.02 | ▼ −3.77% | ▼ −1.80% | $0.8910 (−15.94%) |
Apr 8, 2026 28w ago | 8-K | $1.25 $1.15 | ▼ −8.00% | ▼ −15.57% | $0.8910 (−28.72%) |
Apr 8, 2026 28w ago | 424B5 | $1.25 $1.15 | ▼ −8.00% | ▼ −15.57% | $0.8910 (−28.72%) |
Mar 5, 2026 33w ago | 8-K | $1.16 $1.26 | ▲ +8.62% | ▲ +10.67% | $0.8910 (−23.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers